{"changes":[],"country":"US","description":"Life Biosciences develops partial epigenetic reprogramming therapies that revert aged cells to a younger functional state for age-related disease. It targets patients with optic neuropathies and liver disease first, expanding to broader aging conditions. Lead candidate ER-100 cleared FDA investigational use in January 2026, targeting causes rather than symptoms.","domain":"lifebiosciences.com","employees":null,"founded":2016,"fundingTotalQuarantined":false,"githubOrg":"unknown","githubStars":null,"industry":"bio","investors":[],"lat":42.358834,"lng":-71.05783,"location":"Boston, United States","name":"Life Biosciences","rounds":[{"amountQuarantined":false,"amountUsd":80000000,"currency":"USD","date":"2026-04-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-25","status":"attributed","url":null},"status":"attributed","type":"series-d+","url":null}],"slug":"lifebiosciences-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-25","status":"attributed","url":null},{"fact":"existence","publisher":"lifebiosciences.com","retrievedAt":"2026-05-25","status":"self-reported","url":"https://lifebiosciences.com"},{"fact":"description","publisher":"lifebiosciences.com","retrievedAt":"2026-05-25","status":"self-reported","url":"https://lifebiosciences.com"}],"stage":"series-b+","techStack":["unknown"],"totalRaisedUsd":150000000,"updatedAt":"2026-05-25"}